In our new blog “Ypsomed Pulse”, we want to share expertise and knowledge with our customers, partners, and other players in and around the industry because we believe in the benefit of collective growth and progress.

Immerse yourself in the future of subcutaneous drug administration with large-volume autoinjectors. Our comprehensive literature review reveals their transformative potential to break barriers in delivering single large-volume doses. Explore how these innovations are reshaping the landscape, paving the way for new approaches to drug delivery and accelerating the shift from hospital-based infusion to home self-injection.

UnoPen and YpsoPen are two of Ypsomed’s platforms developed and customized on behalf of various pharma customers for patients dependent on insulin but also GLP-1, hGH, FSH and PTH. Demand for these devices has now exceeded the total of 100 million UnoPen and 10 million YpsoPen delivered units.